{
    "nct_id": "NCT01097096",
    "title": "A 90-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study in Patients With Mild Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Abeta-specific Antibody Response Following Repeated i.m. Injections of Adjuvanted CAD106",
    "status": "COMPLETED",
    "last_update_time": "2021-03-02",
    "description_brief": "This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "CAD106 \u2014 active A\u03b2 immunotherapeutic vaccine (A\u03b21\u20136 peptide coupled to a Q\u03b2 virus\u2011like particle), adjuvanted; given intramuscularly in the described trial."
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The intervention is an active immunotherapy (vaccine) designed to elicit A\u03b2\u2011specific antibodies and thus target amyloid\u2011\u03b2 pathology with the goal of disease modification rather than symptomatic cognitive enhancement. \ue200cite\ue202turn0search6\ue202turn0search1\ue201",
        "Act: Key trial details \u2014 repeated intramuscular injections of adjuvanted CAD106 in patients with mild AD in a 90\u2011week randomized, double\u2011blind, placebo\u2011controlled study; CAD106 has been described in trials as inducing A\u03b2\u2011specific IgG responses. \ue200cite\ue202turn0search1\ue202turn0search0\ue201",
        "Reflect: Classification check \u2014 because CAD106 is a biologic vaccine that specifically targets A\u03b2 pathology (active immunization), it fits the 'disease\u2011targeted biologic' category. This is supported by multiple Phase I/II reports and trial publications. No evidence in the description suggests the trial is a symptomatic cognitive enhancer or a neuropsychiatric\u2011symptom trial. \ue200cite\ue202turn0search3\ue202turn0search6\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational product is CAD106, a second-generation active immunotherapy composed of multiple copies of the A\u03b21\u20136 peptide coupled to a Q\u03b2 virus\u2011like particle designed to elicit A\u03b2\u2011specific antibodies and avoid A\u03b2\u2011specific T\u2011cell activation\u2014i.e., it directly targets amyloid\u2011\u03b2 pathology. \ue200cite\ue202turn0search7\ue202turn0search2\ue201",
        "Act: Key extracted trial details and mechanisms \u2014 90\u2011week, multicenter, randomized, double\u2011blind, placebo\u2011controlled Phase II study in mild AD with repeated intramuscular (i.m.) injections of adjuvanted CAD106; CAD106 has been shown to induce A\u03b2\u2011specific IgG responses in a substantial proportion of treated patients and showed PET evidence of target engagement in prior studies. These facts identify the intervention as a disease\u2011targeted biologic acting on amyloid\u2011\u03b2. \ue200cite\ue202turn0search0\ue202turn0search7\ue202turn0search3\ue201",
        "Reflect: Classification check \u2014 CADRO category A) Amyloid beta is the most specific fit because the vaccine\u2019s mechanism is to generate antibodies against A\u03b2 (not to modulate tau, inflammation, synaptic receptors, metabolism, or perform diagnostics). The trial description and primary publications explicitly describe A\u03b2 targeting and immunogenicity; there is no indication of a multi\u2011target mechanism or a non\u2011therapeutic/diagnostic aim, so 'A) Amyloid beta' is appropriate. \ue200cite\ue202turn0search6\ue202turn0search5\ue201",
        "Web search results used (primary sources): PubMed/PMC Phase II CAD106 study describing 90\u2011week randomized trial, safety, tolerability and A\u03b2\u2011IgG responses. \ue200cite\ue202turn0search7\ue201",
        "PubMed abstract of the 90\u2011week Phase IIb CAD106 study (safety/tolerability/immunogenicity). \ue200cite\ue202turn0search0\ue201",
        "Wiley/Alzheimer\u2019s & Dementia reports and meeting abstracts describing CAD106 first\u2011in\u2011man and Phase II biomarker/immunogenicity findings. \ue200cite\ue202turn0search1\ue202turn0search6\ue201",
        "NCBI Bookshelf / review summarizing CAD106 composition (A\u03b21\u20136 coupled to Q\u03b2 VLP), development history and mechanism. \ue200cite\ue202turn0search2\ue201",
        "Alzheimer\u2019s Research & Therapy review table listing CAD106 as an A\u03b21\u20136/Q\u03b2 vaccine given i.m. and classified as active A\u03b2 immunotherapy. \ue200cite\ue202turn0search5\ue201"
    ]
}